BC Advantage Funds Surpasses $9.5 million in Venture Fund Sales

Advantage Life Science Fund II now offered for sale

Vancouver, December 3, 2007 - BC Advantage Funds (VCC) Ltd. announced today that the Advantage Venture Fund (BCA100 on Fundserve) has surpassed $9,550,000 in sales. With less than $450,000 remaining, the fund is expected to sell out within the week.

Advantage's COO and Partner, David Raffa, commented, "This has been an exceptional fund raising year for our Venture Fund and will be our earliest sell out since inception. We are very grateful to our investors for the continuing confidence they have shown in us."

BC Advantage Funds also announced that the Advantage Life Science Fund II (formerly known as Pender NDI Life Sciences Fund) has completed its prospectus filing and is now being offered for sale (BCA800 on Fundserve).

"We have had the opportunity to evaluate the Advantage Life Science Fund I portfolio companies and we are actively working to make new investments in the fund and increase shareholder value," stated CEO and Partner, Frank Holler. "Our first life sciences fund, Advantage Life Science Fund I, was launched at a $10.00 net asset value in August 2001 and we have since increased the NAV of that fund to over $22.00, including a special dividend of $10.00 distributed to shareholders this past spring."

The Advantage Life Science Fund II has approximately $6,000,000 of 2007 tax credit allocation remaining for sale.

About Advantage

Advantage offers everyone in BC the opportunity to invest in some of the Province's most promising life science, technology and clean-technology companies. Advantage investors receive a 30% refundable tax credit from the BC government on investments of up to $200,000 per year.

For more information about Advantage, please review our prospectus, visit our website at www.bcadvantagefunds.com or contact our Vice President, Sales and Marketing, Ray Matthews at rmatthews@lionscapital.com or 604.818.7778.

« Back to News